A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology

Inclusion Criteria: * Participants with the Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 * Locally advanced or metastatic (stage IIIB or IV) squamous NSCLC * No prior systemic chemotherapy, targeted therapy for metastatic NSCLC * Evidence of at least one radiologically measurable lesion as per RECIST version 1.1 * Adequate hematological, liver and renal function * Participants must agree to either remain completely abstinent or to use effective contraceptive methods from screening until 6 months after the last dose of study treatment * Histologically confirmed squamous NSCLC participants eligible for enrollment must provide archival tumor biopsy tissue or if unavailable must be willing to undergo a fresh pretreatment primary tumor or metastatic biopsy * Participants with Gilbert's Syndrome will be eligible for the study Exclusion Criteria: * Concurrent therapy with any other investigational drug * History or clinical evidence of central nervous system (CNS) primary tumors or metastases * Evidence of significant, uncontrolled concomitant diseases, which could affect compliance with the protocol or interpretation of results, including uncontrolled diabetes mellitus and/or significant cardiovascular disease or uncontrolled infection * Any other diseases, metabolic dysfunction, a physical examination finding or a clinical laboratory finding, giving reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug * Major surgery or significant traumatic injury less than (\<) 28 days prior to the first study treatment infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment * Pregnant or breast-feeding women * History of other malignancies that could affect compliance with protocol or interpretation of results. Participants with malignancies diagnosed more than 5 years prior to study day one, adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer are generally eligible